Marking Women's Health Month, Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, detailed how value assessments can address health care imbalances for women.
Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, detailed how value assessments can address health care imbalances for women, marking Women's Health Month.
Transcript
How do value assessments currently address imbalances in health care for women and what still needs to be improved?
Phares: So, currently, there are attempts to address imbalances but they still exist. For instance, if you think back to when migraine medications were being assessed, a lot of the issues that really impact what makes those medications important to women in particular, who are the most predominant group that suffers from migraine, we're not considered. So, those are things like their ability to function and to care for their families. What they're trying to do in HTA [health technology assessment] now is to be more inclusive of those; to look at things like caregiver burden, again, something that women are more likely to be doing than men; and then quality of life issues around your ability to do normal activities, like care for children, go to work, etc.
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen